Ivković Maja, Damjanović Aleksandar, Jovanović Aleksandar, Cvetić Tijana, Jasović-Gasić Miroslava
Institute for psychiatry, Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia.
Psychiatr Danub. 2009 Jun;21(2):187-93.
Mood stabilizer augmentation of standard antidepressant drugs has been shown to be effective in treatment-resistant depression. Despite the reported high overall efficacy, lithium has been relatively underused in recent years. Lamotrigine, a novel anticonvulsant recently recognized as a mood stabilizer, seems to have putative antidepressive properties. The aim of the study was to investigate lamotrigine efficacy and tolerability as antidepressant augmentation for unipolar treatment-resistant depression compared to lithium.
88 patients suffering from treatment-resistant Major depressive disorder, having acute recurrent depressive episodes according to DSM-IV criteria, were enrolled in the study. This was an open-label trial with a flexible dosing regimen. All patients, received antidepressants in full therapeutic doses. They were divided into two augmentation groups: 46 patients received 50-200 mg/day lamotrigine, and 42 patients received 600-1200 mg/day lithium. The Hamilton Rating Scale for Depression (HAM-D) and The Clinical Global Impression scale (CGI) were used to monitor therapeutic efficacy. Patients were evaluated weekly for an 8 week treatment period.
The HAM-D total score was significantly reduced in both treatment groups at the study endpoint, without any difference between the groups. However, significant clinical improvement was reached within the second treatment week in the lamotrigine group compared to the lithium group (p=0.01 vs. lithium). Lamotrigine showed significant efficacy on the HAM-D item 1(depressed mood; p=0.01), item 7 (work and interest; p=0.01) and CGI-Improvement scale (p=0.02). The drop-out rate due to treatment failure was lower in the lamotrigine group (n=1) compared to the lithium (n=4) group. Also, the incidence of side effects did not differ between the groups.
Our results suggest that lamotrigine could be useful as augmentation of antidepressants for treatment-resistant unipolar depression. Also, lamotrigine may accelerate the onset of antidepressant action, and therefore might be useful in treatment of major depression in general.
标准抗抑郁药物联合心境稳定剂已被证明对难治性抑郁症有效。尽管总体疗效较高,但近年来锂盐的使用相对不足。拉莫三嗪是一种新型抗惊厥药,最近被确认为心境稳定剂,似乎具有潜在的抗抑郁特性。本研究的目的是比较拉莫三嗪与锂盐作为单相难治性抑郁症抗抑郁增效剂的疗效和耐受性。
88例符合DSM-IV标准的患有难治性重度抑郁症且有急性复发性抑郁发作的患者纳入本研究。这是一项采用灵活给药方案的开放标签试验。所有患者均接受全治疗剂量的抗抑郁药治疗。他们被分为两个增效治疗组:46例患者接受50 - 200毫克/天的拉莫三嗪治疗,42例患者接受600 - 1200毫克/天的锂盐治疗。采用汉密尔顿抑郁量表(HAM-D)和临床总体印象量表(CGI)监测治疗效果。在为期8周的治疗期间,每周对患者进行评估。
在研究终点时,两个治疗组的HAM-D总分均显著降低,两组之间无差异。然而,与锂盐组相比,拉莫三嗪组在治疗第二周时即达到显著的临床改善(与锂盐组相比,p = 0.01)。拉莫三嗪在HAM-D项目1(情绪低落;p = 0.01)、项目7(工作和兴趣;p = 0.01)和CGI改善量表(p = 0.02)上显示出显著疗效。与锂盐组(n = 4)相比,拉莫三嗪组因治疗失败导致的脱落率较低(n = 1)。此外,两组之间副作用的发生率没有差异。
我们的结果表明,拉莫三嗪可作为难治性单相抑郁症抗抑郁药的增效剂。此外,拉莫三嗪可能会加速抗抑郁作用的起效,因此可能对一般重度抑郁症的治疗也有用。